Therapeutic Response

CD33 + status confers therapeutic sensitivity to Cytarabine in combination with Daunorubicin and Gemtuzumab ozogamicin in patients with Acute Myeloid Leukemia.

Statements

Source and description
Mylotarg (gemtuzumab ozogamicin) [product monograph]. HC. Health Canada approved gemtuzumab ozogamicin in combination with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia.